QQ客服 官方微博 反馈留言

	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
	Wu, Yi-Long; Hirsh, Vera; Sequist, Lecia V.; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Schuler, Martin; Mok, Tony; Yamamoto, Nobuyuki
刊名	The Patient - Patient-Centered Outcomes Research
	2018
卷号	11期号:1页码:131-141
ISSN号	1178-1653
DOI	10.1007/s40271-017-0287-z
URL标识	查看原文
WOS记录号	WOS:000422626600012
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3324197
专题	中南大学
作者单位	[Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China.
推荐引用方式 GB/T 7714	Wu, Yi-Long,Hirsh, Vera,Sequist, Lecia V.,et al. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)[J]. The Patient - Patient-Centered Outcomes Research,2018,11(1):131-141.
APA	Wu, Yi-Long.,Hirsh, Vera.,Sequist, Lecia V..,Hu, Cheng-Ping.,Feng, Jifeng.,...&Yang, James Chih-Hsin*.(2018).Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).The Patient - Patient-Centered Outcomes Research,11(1),131-141.
MLA	Wu, Yi-Long,et al."Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)".The Patient - Patient-Centered Outcomes Research 11.1(2018):131-141.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。